ZK Prog-R-BAlternative Names: Progesterone receptor blocker ZK Prog-R-B
Latest Information Update: 02 Jul 2004
At a glance
- Originator Bayer Schering Pharma
- Mechanism of Action Progesterone receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 02 Jul 2004 No development reported - Phase-I for Cancer in Europe (unspecified route)
- 24 Jul 2001 Phase-I clinical trials for Cancer in Europe (Unknown route)
- 24 Jul 2001 New profile